Conditions associated with first-time VTE
| Thrombotic risk factor, n (%) . | No. of patients with first instance of VTE (N = 632) . |
|---|---|
| CVC | 257 (40.7) |
| Hormonal contraception (females only) | 84 (25.7); n = 327 |
| Surgery within 6 weeks of VTE event | 162 (25.6) |
| Infection | 115 (18.2) |
| Cancer at time of VTE | 113 (17.9) |
| Congenital thrombophilia | 93 (14.7) |
| Anatomic venous abnormality | 80 (12.7) |
| Asparaginase within 6 weeks of VTE | 45 (7.1) |
| IF | 27 (4.3) |
| IBD | 21 (3.3) |
| Antiphospholipid syndrome | 11 (1.7) |
| Systemic lupus erythematosus | 9 (1.4) |
| Cystic fibrosis | 9 (1.4) |
| Nephrotic syndrome | 6 (0.9) |
| No identified risk factor | 56 (8.9) |
| Thrombotic risk factor, n (%) . | No. of patients with first instance of VTE (N = 632) . |
|---|---|
| CVC | 257 (40.7) |
| Hormonal contraception (females only) | 84 (25.7); n = 327 |
| Surgery within 6 weeks of VTE event | 162 (25.6) |
| Infection | 115 (18.2) |
| Cancer at time of VTE | 113 (17.9) |
| Congenital thrombophilia | 93 (14.7) |
| Anatomic venous abnormality | 80 (12.7) |
| Asparaginase within 6 weeks of VTE | 45 (7.1) |
| IF | 27 (4.3) |
| IBD | 21 (3.3) |
| Antiphospholipid syndrome | 11 (1.7) |
| Systemic lupus erythematosus | 9 (1.4) |
| Cystic fibrosis | 9 (1.4) |
| Nephrotic syndrome | 6 (0.9) |
| No identified risk factor | 56 (8.9) |